In today’s briefing:
- Mao Geping Cosmetics Pre-IPO – Riding on the Founder’s Reputation
- QuantumPharm IPO Trading – Lukewarm Insti Demand Combined with a Tight Float at Listing
- Medtide Pre-IPO Tearsheet
- Telix Pharmaceutical US ADS – Momentum Remains Strong, Offering Would Triple Its Cash Base
Mao Geping Cosmetics Pre-IPO – Riding on the Founder’s Reputation
- Mao Geping Cosmetics is looking to raise around US$300m in its upcoming Hong Kong IPO.
- Mao Geping Cosmetics (MGC) operates in the premium beauty segment. Operating via its two brands, MAOGEPING and Love Keeps, MGC offers a wide range of color cosmetics and skincare products.
- In this note, we look at the company’s past performance.
QuantumPharm IPO Trading – Lukewarm Insti Demand Combined with a Tight Float at Listing
- QuantumPharm (QUP HK) raised US$126m from its Hong Kong IPO.
- QuantumPharm is a R&D platform, utilizing quantum physics-based first-principles calculation, advanced AI, high-performance cloud computing, and scalable and standardized robotic automation to provide drug and material science R&D solutions.
- We have covered various aspects of the deal in our previous note. In this note, we will talk about the demand and trading dynamics.
Medtide Pre-IPO Tearsheet
- Medtide (1268709D CH) is looking to raise at least US$100m in its upcoming HK IPO. The deal will be run by Morgan Stanley and Citic Securities.
- Medtide is the third largest peptide-focused contract research, development and manufacturing organization (CRDMO) worldwide in terms of sales revenue in 2023, according to F&S.
- Its full-cycle services range from early-stage discovery, pre-clinical research and clinical development to commercial-stage production.
Telix Pharmaceutical US ADS – Momentum Remains Strong, Offering Would Triple Its Cash Base
- Telix Pharmaceuticals (TLX AU) is looking to raise around US$190m in its US ADS listing. The bookrunners on the deal are Jefferies, Morgan Stanley, Truist Securities, and William Blair.
- TLX is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals.
- In this note, we talk about the updates since our last note and current deal dynamics.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
